ArticleInternational journal of dermatology2026
Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies.
Article in International journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionImmune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low-grade immune-related adverse events (irAEs) are associated with prolonged survival, high-grade irAEs have been associated with poorer survival. Cutaneous immune-related adverse events (cirAEs) affect up to 20%-40% of patients treated with ICIs. We investigated the association between cirAES and the outcomes of progression-free survival (PFS) and overall survival (OS) in advanced solid organ malignancies.
methodsA retrospective analysis of patients receiving ICIs for stage IV solid organ malignancies was conducted at Beaumont RCSI Cancer Centre, Dublin, Ireland, between January 1, 2012, and June 30, 2020. Eligible participants included those who commenced therapy during this period, having received at least one cycle of ICI treatment, with or without chemotherapy, for histologically confirmed advanced solid organ malignancies.
resultsAmong 278 analyzed patients, 19% (53/278) experienced any cirAES. The most common cirAEs included psoriasis (23%) and pruritus (15%). cirAES were associated with significantly improved PFS (median 47.3 months vs. 18.3 months, p < 0.01) and OS (median 60.0 months vs. 26.0 months, p < 0.01). Patients with prior systemic therapy had a decreased risk of cirAES (odds ratio = 0.44, p = 0.02), and multivariate analysis confirmed that cirAES was independently associated with improved PFS and OS.
conclusionOur study supports that cirAES may be associated with improved patient outcomes and that prior systemic therapy may be associated with a reduced risk of cirAES. Future research should focus on multi-institutional collaborations based on prospective irAE data to better understand the impact of specific irAEs on clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.